Medpace Holdings (FRA:01P) Cyclically Adjusted Revenue per Share: €40.83 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:01P Medpace Holdings Inc FRA:01P
95 GF Score
Price €530.40
GF Value €463.14
Valuation Modestly Overvalued
! 2 Warning Signs
View Full Analysis

What is Medpace Holdings Cyclically Adjusted Revenue per Share?

Medpace Holdings FRA:01P +0.49% 95 Cyclically Adjusted Revenue per Share is €40.83 as of Jun. 2026. GuruFocus rates FRA:01P with a GF Score™ of 95/100 and a GF Value™ of €463.14 (Modestly Overvalued). The stock has 2 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Medpace Holdings's adjusted revenue per share for the three months ended in Jun. 2026 was €21.502. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is €40.83 for the trailing ten years ended in Jun. 2026.

During the past 12 months, Medpace Holdings's average Cyclically Adjusted Revenue Growth Rate was 26.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

As of today (2026-07-25), Medpace Holdings's current stock price is €530.40. Medpace Holdings's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 was €40.83. Medpace Holdings's Cyclically Adjusted PS Ratio of today is 12.99.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Medpace Holdings was 15.39. The lowest was 8.20. And the median was 10.94.


Medpace Holdings  (FRA:01P) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Medpace Holdings's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=530.40/40.83
=12.99

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Medpace Holdings was 15.39. The lowest was 8.20. And the median was 10.94.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Medpace Holdings Cyclically Adjusted Revenue per Share Related Terms


Medpace Holdings Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Medpace Holdings's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Medpace Holdings Cyclically Adjusted Revenue per Share Chart

Medpace Holdings Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 32.08 35.39

Medpace Holdings Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 31.38 33.38 35.39 37.95 40.83

FRA:01P vs ICLR, RVTY, CRL: Cyclically Adjusted Revenue per Share Comparison

For the Diagnostics & Research subindustry, Medpace Holdings's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Medpace Holdings Cyclically Adjusted PS Ratio vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Medpace Holdings's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Medpace Holdings's Cyclically Adjusted PS Ratio falls into.


FRA:01P
95GF Score
Medpace Holdings Inc FRA:01P
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Medpace Holdings Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Medpace Holdings's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=21.502/333.9520*333.9520
=21.502

Current CPI (Jun. 2026) = 333.9520.

Medpace Holdings Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 2.553 241.428 3.531
201612 2.430 241.432 3.361
201703 2.401 243.801 3.289
201706 2.316 244.955 3.157
201709 2.360 246.819 3.193
201712 2.523 246.524 3.418
201803 3.628 249.554 4.855
201806 3.972 251.989 5.264
201809 4.138 252.439 5.474
201812 4.532 251.233 6.024
201903 4.765 254.202 6.260
201906 5.068 256.143 6.608
201909 5.189 256.759 6.749
201912 5.476 256.974 7.116
202003 5.494 258.115 7.108
202006 4.877 257.797 6.318
202009 5.179 260.280 6.645
202012 5.664 260.474 7.262
202103 5.785 264.877 7.294
202106 6.125 271.696 7.528
202109 7.789 274.310 9.483
202112 5.631 278.802 6.745
202203 8.264 287.504 9.599
202206 9.860 296.311 11.113
202209 12.017 296.808 13.521
202212 11.486 296.797 12.924
202303 12.608 301.836 13.950
202306 13.472 305.109 14.746
202309 14.529 307.789 15.764
202312 14.351 306.746 15.624
202403 14.692 312.332 15.709
202406 15.290 314.175 16.252
202409 14.975 315.301 15.861
202412 16.076 315.605 17.011
202503 16.562 319.799 17.295
202506 17.948 322.561 18.582
202509 19.511 324.800 20.061
202512 20.878 324.054 21.516
202603 21.104 330.213 21.343
202606 21.502 333.952 21.502

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of €40.83 mean?
Medpace Holdings (FRA:01P) has a Cyclically Adjusted Revenue per Share of €40.83 as of Jun. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Medpace Holdings and its competitors.
Is Medpace Holdings' Cyclically Adjusted Revenue per Share too high?
Medpace Holdings' current Cyclically Adjusted Revenue per Share is €40.83. Overall, Medpace Holdings has a GF Score™ of 95/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Medpace Holdings' Cyclically Adjusted Revenue per Share compare to ICLR and RVTY?
Medpace Holdings' Cyclically Adjusted Revenue per Share of €40.83 can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Medical Diagnostics & Research company?
A good Cyclically Adjusted Revenue per Share depends on the Medical Diagnostics & Research industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Medpace Holdings and its competitors. Medpace Holdings's current Cyclically Adjusted Revenue per Share is €40.83. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medpace Holdings stock overvalued right now?
Based on GuruFocus' analysis, Medpace Holdings (FRA:01P) is currently considered Modestly Overvalued. The stock's GF Value™ is €463.14, compared to a current price of €530.40 — trading 14.5% above its estimated fair value. The current Cyclically Adjusted Revenue per Share is €40.83. Medpace Holdings' overall GF Score™ is 95/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Medpace Holdings (FRA:01P), the current Cyclically Adjusted Revenue per Share is €40.83 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Medpace Holdings (FRA:01P) Overvalued in 2026?

Based on GuruFocus' analysis, Medpace Holdings stock appears to be overvalued. The current stock price of €530.40 is trading 14.5% above its estimated GF Value™ of €463.14. GuruFocus considers Medpace Holdings to be Modestly Overvalued.

Key valuation signals for FRA:01P:

  • Cyclically Adjusted Revenue per Share: €40.83
  • GF Value™: €463.14 vs. price of €530.40 (14.5% above fair value)
  • GF Score™: 95/100 with 2 warning signs

No single metric tells the full story. See the FRA:01P stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Medpace Holdings Business Description

Other Exchanges MEDP:USAMEDP:Mexico
Address 5375 Medpace Way, Cincinnati, OH, USA, 45227
Medpace is a late-stage contract research organization that provides full-service drug-development and clinical trial services to small and midsize biotechnology, pharmaceutical, and medical device firms. It also offers ancillary services, including bioanalytical laboratory services and imaging capabilities. The company was founded over 30 years ago and has more than 5,400 employees across 40 countries. Medpace is headquartered in Cincinnati, Ohio, and its operations are primarily based in the US, with additional presence in Europe, Asia, South America, Africa, and Australia. Cinven, a global private equity firm, acquired Medpace for $915 million in 2014 and exited its investment in 2018.
95GF Score

Get the complete analysis for FRA:01P

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€530.40
Price
€463.14
GF Value